trial · primary record
Rozanolixizumab
Ocular Myasthenia Gravis
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 100 |
| Primary completion | 2031-03-17 |
| Primary endpoint | Incidence of treatment-emergent adverse events (TEAEs) |
| Registry ID | NCT07465289 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:20.402Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07465289
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.